​A “busy person” all his life, 73-year-old Gerard ‘Gerry’ Heaney from Craigavon was diagnosed in 2018 with the rare and ...

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

Ataxia is a condition caused by damage in cerebellum, a part of the brain, that leads to poor muscle control affecting movement. In an interview with HT Lifestyle, Dr Aniruddha More, consultant ...

IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA® (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...

Rheumatoid arthritis (RA) is a common autoimmune disease in which the immune system recognizes autoantigens on otherwise healthy joint tissues as foreign invaders, inducing a localized inflammatory ...